⌕
Cencora · COR · NYSE
Tenet 38 · Weak
Compare
$350.56−1.79%At closeTenet 38 · Weak
$350.56−6.38 (−1.79%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD

Cencora (COR) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is COR's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● ReutersNov 13, 2026 · 11:46 ET
US FTC sues to block Cencora's $3.5 billion sale of veterinary unit to Covetrus

The US antitrust regulator filed a lawsuit on Friday in a New York federal court to ​block Cencora's $3.5 billion sale of its MWI ‌Animal Health unit to veterinary supplier Covetrus, arguing the deal would raise costs fo…

COR −1.8% todayRead at source ↗
● Defense WorldNov 12, 2026 · 03:52 ETEARNINGS EXPECTED BY FEB 3
Cencora, Inc. $COR Shares Bought by Ethic Inc.

Ethic Inc. lifted its stake in Cencora, Inc. (NYSE: COR) by 22.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,405 shares of the company'…

COR −1.8% todayRead at source ↗
● Zacks Investment ResearchNov 6, 2026 · 09:36 ET
3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility

BDX, COR and UNF recently hiked dividends, offering investors steady income opportunities as market volatility, inflation and economic uncertainty persist.…

COR −1.8% todayRead at source ↗
● MarketBeatNov 5, 2026 · 02:14 ETEARNINGS EXPECTED BY FEB 3
What Cencora (COR) Said on Its Q4 Earnings Call

Cencora NYSE: COR reported higher fiscal fourth-quarter revenue and adjusted earnings as specialty drug sales and its acquisition of OneOncology contributed to growth. The company also introduced a new reporting structur…

COR −1.8% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 14:56 ETEARNINGS EXPECTED BY FEB 3
Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand

COR's Q4 earnings and revenues beat estimates as specialty drug demand fuels growth and margins expand. The company raises its fiscal 2027 outlook.…

COR −1.8% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 13:14 ETEARNINGS EXPECTED BY FEB 3
Cencora, Inc. (COR) Q4 2026 Earnings Call Transcript

Cencora, Inc. (COR) Q4 2026 Earnings Call Transcript…

COR −1.8% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 10:31 ETEARNINGS EXPECTED BY FEB 3
Cencora (COR) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the…

COR −1.8% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 08:51 ETEARNINGS EXPECTED BY FEB 3
Cencora (COR) Surpasses Q4 Earnings and Revenue Estimates

Cencora (COR) came out with quarterly earnings of $4.66 per share, beating the Zacks Consensus Estimate of $4.56 per share. This compares to earnings of $3.84 per share a year ago.…

COR −1.8% todayRead at source ↗
● Business WireNov 4, 2026 · 06:35 ETCOMPANY'S OWN WORDS
Cencora Announces New Organizational and Reporting Structure to Enhance Visibility and Focus

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it is realigning its corporate and reporting structure to strengthen execution and visibility. “Over the last two years, Cencora has take…

COR −1.8% todayRead at source ↗
● Business WireNov 4, 2026 · 06:35 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 3
Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2026 fourth quarter ended September 30, 2026, revenue increased 5.5 percent to $88.4 billion. Revenue increased 5.0 per…

COR −1.8% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 10:46 ET
Why Cencora (COR) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.…

COR −1.8% todayRead at source ↗
● Zacks Investment ResearchOct 30, 2026 · 12:01 ETEARNINGS EXPECTED BY FEB 3
Cencora Gears Up to Report Q4 Results: How to Play the Stock?

COR's Q4 earnings are likely to benefit from strong specialty pharma demand and MSO growth, but pricing pressures and higher interest costs may weigh on results.…

COR −1.8% todayRead at source ↗
● Zacks Investment ResearchOct 30, 2026 · 10:16 ETEARNINGS EXPECTED BY FEB 3
Unveiling Cencora (COR) Q4 Outlook: Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September …

COR −1.8% todayRead at source ↗
● Zacks Investment ResearchOct 28, 2026 · 11:01 ETEARNINGS EXPECTED BY FEB 3
Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth

Cencora (COR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

COR −1.8% todayRead at source ↗
● Zacks Investment ResearchOct 28, 2026 · 10:41 ET
Cencora to Acquire AON in $2.4B Deal to Expand Oncology Network

COR's $2.4B acquisition of AON aims to expand its oncology services platform, strengthen community cancer care and support long-term growth.…

COR −1.8% todayRead at source ↗
● ReutersOct 21, 2026 · 07:38 ET
Cencora to acquire American Oncology Network in $2.4 billion deal

Cencora to acquire American Oncology Network in $2.4 billion deal…

COR −1.8% todayRead at source ↗
● Business WireOct 21, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology

CONSHOHOCKEN, Pa. & FORT MYERS, Fla.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. (“AON”) (OTCQX: AONC), a physician-led netw…

COR −1.8% todayRead at source ↗
● Defense WorldOct 19, 2026 · 04:50 ETEARNINGS EXPECTED BY FEB 3
IFP Advisors Inc Purchases 14,078 Shares of Cencora, Inc. $COR

IFP Advisors Inc raised its holdings in Cencora, Inc. (NYSE: COR) by 227.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,264 shares of …

COR −1.8% todayRead at source ↗
● Defense WorldOct 19, 2026 · 04:17 ETEARNINGS EXPECTED BY FEB 3
Cencora, Inc. $COR Stake Increased by Frank Rimerman Advisors LLC

Frank Rimerman Advisors LLC grew its holdings in Cencora, Inc. (NYSE: COR) by 235.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,336 …

COR −1.8% todayRead at source ↗
● Business WireOct 2, 2026 · 08:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 3
Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the opening of trading on …

COR −1.8% todayRead at source ↗
● Business WireSep 25, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Cencora Elects Robert E. Sanchez to Its Board of Directors

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026. Mr. Sanchez is the Executi…

COR −1.8% todayRead at source ↗
● Business WireSep 2, 2026 · 08:30 ET
Cencora's Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solutions, Cell and Gene The…

COR −1.8% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 3. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just COR · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.